These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 9241127

  • 1. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA.
    N Engl J Med; 1997 Aug 07; 337(6):382-7. PubMed ID: 9241127
    [Abstract] [Full Text] [Related]

  • 2. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.
    J Rheumatol; 2000 Oct 07; 27(10):2424-31. PubMed ID: 11036840
    [Abstract] [Full Text] [Related]

  • 3. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.
    J Rheumatol; 2003 Dec 07; 30(12):2673-9. PubMed ID: 14719212
    [Abstract] [Full Text] [Related]

  • 4. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ.
    N Engl J Med; 1990 Jul 12; 323(2):73-9. PubMed ID: 2113611
    [Abstract] [Full Text] [Related]

  • 5. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG.
    N Engl J Med; 1998 Jul 30; 339(5):292-9. PubMed ID: 9682041
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
    Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B.
    J Clin Endocrinol Metab; 1998 Apr 30; 83(4):1128-33. PubMed ID: 9543129
    [Abstract] [Full Text] [Related]

  • 9. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 30; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec 30; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH.
    N Engl J Med; 1990 May 03; 322(18):1265-71. PubMed ID: 2109197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A, Snelder AA, Mulder H.
    Am J Med; 1995 Sep 03; 99(3):235-42. PubMed ID: 7653482
    [Abstract] [Full Text] [Related]

  • 18. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM, Hillner BE.
    J Rheumatol; 2003 Jan 03; 30(1):132-8. PubMed ID: 12508402
    [Abstract] [Full Text] [Related]

  • 19. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
    Storm T, Steiniche T, Thamsborg G, Melsen F.
    J Bone Miner Res; 1993 Feb 03; 8(2):199-208. PubMed ID: 8442438
    [Abstract] [Full Text] [Related]

  • 20. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
    Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J.
    Ann Rheum Dis; 1998 Dec 03; 57(12):724-7. PubMed ID: 10070271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.